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The pathogenesis of Charcot neuroarthropathy (CN) has been poorly understood by clinicians and scientists
alike. Current researchers have made progress toward understanding the cause of CN and possible treatment
options. The authors review the current literature on the pathogenesis of this debilitating disorder and
attempt to explain the roles of inflammation, bone metabolism, and advanced glycation end products.
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S
ince its first description by Sir William Musgrave
in 1703, the pathogenesis of Charcot neuroarthro-
pathy (CN) has bewildered even the most astute
physicians and scientists. In 1883, Jean-Martin Charcot
described the ‘pied tabe ´tique’ or ‘tabetic foot,’ as tabes
dorsalis was the most common cause of neuroarthro-
pathy at the time (1). Diabetes mellitus has long
surpassed syphilis as the leading cause of CN in the
United States, and the prevalence of diagnosed CN
in patients with diabetes is reported to be 0.08% 7.5%
(2). Although rare, CN is one of the most destructive
complications of diabetes, leading to subluxation, dis-
location, deformity, and ulceration of the foot and ankle
joints. A greater understanding of the pathogenesis of
CN is needed to develop new treatment strategies. This
review article aims to summarize the recent literature
on the pathogenesis of CN at the molecular level and
looks toward therapies that function to antagonize the
pathologic mechanisms.
Uncontrolled inflammation and bone
metabolism
Charcot postulated that neuropathic joints were caused
by an abnormality of blood flow due to denervation:
‘denervation will also be expressed by changes in the
circulation or nutrition if it involves, in addition, nerve
fibers which are vasomotor or trophic’ (translation)
(1). In addition, Charcot recognized the role of acute
inflammation: ‘the joints were inflamed, red and rather
painful, similar to exacerbations of subacute rheuma-
toid arthritis’ (translation) (3). Nearly 150 years later,
researchers have found molecular evidence to support
Charcot’s observation of acute inflammation. Indeed, it
is the uncontrolled inflammation that results in the
final common pathway for decreased bone density in
CN: osteoclast osteoblast imbalance. Under normal
circumstances, bone undergoes a constant remodeling
process, with an intricate homeostasis between bone
resorption by osteoclasts and bone formation by osteo-
blasts. Gough and colleagues proved that excessive
osteoclastic activity occurs in patients with acute CN
(4). They studied four groups: patients with acute CN,
chronic CN, diabetic controls, and non-diabetic controls.
Using radioimmunoassay of blood samples from the
dorsal venous arch, this group of researchers found a
statistically significant increase in the pyridinoline cross-
linked carboxy-terminal telopeptide domain of type 1
collagen, which is indicative of osteoclast activity, in
the acute CN group (pB0.0001). A similar increase
in osteoblast precursors, carboxy-terminal propeptide
of type 1 collagen was not found, indicating a higher
concentration of osteoclasts than osteoblasts. In addi-
tion, the patients with acute CN showed a significant
increase in levels of alkaline phosphatase, a marker of
bone turnover.
The role of inflammation in upsetting osteoclast 
osteoblast homeostasis was investigated by Baumhauer
et al. (5). The investigators stained 20 surgical bone
specimens of Charcot patients with hematoxylin and
eosin (H&E), interleukin-1 (IL-1) antibody, tumor ne-
crosis factor (TNF) alpha antibody, and interleukin-6
(IL-6) antibody. These inflammatory cytokines lead to
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proliferation, and differentiation. Osteoclasts demon-
strated a moderate pattern of staining for TNF-alpha
and IL-1, and a diffuse pattern of staining for IL-6.
These results suggest that osteoclasts express inflamma-
tory cytokines during the acute and reparative phases of
CN. H&E staining also showed the presence of excessive
numbers of multinucleated osteoclasts in lacunae sur-
rounded by lamellar bone. Uccioli and colleagues further
elucidated the role of inflammation in the Charcot
process as they characterized the cytokine phenotype
of monocytes in patients with acute CN (6). They
studied three groups: patients with acute CN, diabetic
patients with neuropathy, and normal control subjects. In
patients with acute CN, they found monocytes expressing
increased amounts of the proinflammatory cytokines
TNF-alpha, IL-1 beta, and IL-6 as well as decreased
amounts of the anti-inflammatory cytokines Il-4 and
Il-10. Furthermore, monocytes from acute CN subjects
had a marked increase in the percentage of positive
cells and intensity of expression of the costimulatory
surface molecules CD40, CD80, and CD86. In contrast,
there was no statistically significant difference in these
surface molecules among the diabetic control and healthy
control groups (p 0.05). The inability to end the cycle
of aggressive inflammation that is so characteristic of CN
was explained by a resistance to monocyte apoptosis
conferred by IL-1 beta and TNF-alpha. The results of
this study stimulate one to consider anti-TNF-alpha
therapy as a potential treatment for CN.
The role of receptor activator of nuclear factor-
kappa B ligand (RANKL)
The presence of proinflammatory cytokines alone does
not account for the entire influx of osteoclasts in CN.
Receptor activator of nuclear factor-kappa B ligand
(RANKL) has been studied extensively for its role in
activating osteoclasts in diabetic CN. RANKL is an
important mediator of osteoclastogenesis and is essential
in osteoclast formation and modulation (Fig. 1). The
antagonist of the RANKL pathway is osteoprotegrin
(OPG). Jeffcoate suggested that disruption of the
RANKL/OPG pathway is responsible for both vascular
smooth muscle calcification and the osteopenia seen in
CN (7). Three years later, Mabilleau and colleagues
performed an elegant study that demonstrated the role
of RANKL in CN and also suggested that there may
be a RANKL-independent pathway (8). Osteoclast for-
mation was assessed in peripheral blood samples from
nine diabetic Charcot patients, eight age-matched diabetic
controls, and eight age-matched non-diabetic control
patients. Three isolates were obtained: one in the presence
of macrophage-colony stimulating factor (M-CSF) alone,
one in the presence of M-CSF and RANKL, and
one containing M-CSF, RANKL, and OPG. They found
a statistically significant increase in the formation of
osteoclasts in diabetic Charcot patients when compared
with diabetic control and non-diabetic control patients
(p 0.008) in cultures with M-CSF alone. Percentage
of area bone resorption in Charcot patients was four
times higher than in healthy controls (p 0.005) and
2.9 times higher than in diabetic controls (p 0.008).
The addition of RANKL to the cultures yielded a
significant increase in osteoclastic resorption in the
Charcot group when compared with the diabetic and
healthy control groups (pB0.0001). Finally, the addition
of OPG caused a greater decrease in resorption in the
diabetic and healthy control groups than in the Charcot
group, implicating that there is a RANKL-independent
pathway of bony destruction in CN. This study demon-
strated unequivocally that osteoclast precursor cells in
acute Charcot patients are ‘primed’ to become osteoclasts
withaggressivebehavior.Theauthors ofthis study suggest
that the increased levels of circulating proinflammatory
cytokines, TNF-alpha, IL-6, and IL-8 induce osteoclast
formation independent of RANKL. Indeed, inflamma-
tion is the final common pathway in the pathogenesis
of CN.
To attempt to address the osteoclast osteoblast imbal-
ance, there has been research to evaluate the use
of bisphosphonates in CN. Pitocco et al. performed a
Level 1 study of 20 patients in which the treatment
group received 70 mg of alendronate once weekly, and
the control group received placebo (9). Both groups
were prescribed standard off-loading methods. While
these researchers found significant reductions in hydro-
xyproline and serum C-terminal telopeptide of type 1
collagen (ICTP), markers of bone turnover, they did not
report differences in the resolution of clinical symptoms.
They did, however, demonstrate a reduction in the
serum levels of insulin-like growth factor 1 (IGF-1)
in the treatment group. IGF-1 causes vasodilatation,
adding to the hyperemia that already exists in CN.
This finding prompted the same group of researchers
to study the relationship between IGF-1, neuropathy,
inflammation, and the RANKL system (10). Bisphospho-
nates may decrease IGF-1 and help regulate RANKL,
but their clinical efficacy remains to be proven.
The influence of calcitonin gene-related peptide
(CGRP) and nitric oxide
How is the expression of RANKL increased in patients
with CN? Aside from the supposition that inflammation
itself induces RANKL, there is research that supports
a lack of negative-feedback mechanisms in patients
with diabetes. Peripheral and autonomic neuropathy
can minimize the release of the neuropeptide calcitonin
gene-related peptide (CGRP), which antagonizes the
expression of RANKL. CGRP inhibits osteoclast moti-
lity, recruitment, and differentiation (11). Associated with
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and found in the periosteum and bone marrow. Experi-
ments utilizing fractures in rat femora demonstrated that
CGRP increases at the site of the fracture gap, suggesting
that neuropeptides play an active role in bone remodeling
(12). With a lack of CGRP, osteoclasts are recruited by
RANKL in an unchecked fashion. La Fontaine and
colleagues substantiated the CGRP hypothesis with their
study in 2008 (13). They performed immunohistological
studies in bone samples of three groups: diabetic patients
without neuropathy, diabetic patients with neuropathy,
and diabetic patients with stage 2 or 3 CN. Samples of
bone were collected during reconstructive operations, and
patients with history of ulceration, osteomyelitis, or end-
stage renal disease were excluded. They found a trend
toward significance in comparing CGRP expression, with
the Charcot group having the least amount of CGRP.
Additionally, these researchers looked at the relative
amounts of endothelial nitric oxide synthase (eNOS),
an isoenzyme that regulates nitric oxide production.
Nitric oxide is a free radical that suppresses osteoclasts.
Immunohistochemical studies found a statistically sig-
nificant decrease in eNOS in the Charcot bone compared
with the other two groups (p 0.008); thus, lack of eNOS
is another breakdown in the negative-feedback mechan-
isms that are normally in place for osteoclast modulation
and proliferation.
Advanced glycation end product (AGE)
accumulation
Another mechanism by which RANKL, and thus
osteoclast function, is increased is by accumulation of
advanced glycation end products (AGEs). The formation
of AGEs is driven by hyperglycemia and primarily affects
collagen in tissues with the slowest turnover, such as
cortical bone (14). AGEs have been found to increase
RANKL activation as well as induce osteoblast apoptosis
(15). In patients with diabetes, there is increased forma-
tion of AGEs but a lack of a receptor for AGEs (RAGE).
Witzke and colleagues designed a cross-sectional study
in which they enrolled 80 male subjects: 30 healthy
controls, 30 diabetic patients without Charcot, and 20
diabetic patients with stage-2 CN (14). They found a
significant reduction in calcaneal stiffness in the patients
with CN (pB0.01). In all subjects, there was a positive
correlation between calcaneal bone stiffness and RAGE
concentration, indicating that RAGE is protective against
osteoclastic resorption. CN patients had RAGE values
that were 86% lower than control subjects and 50%
lower than diabetics without CN (pB0.05). In addition,
these researchers found an elevated level of osteocalcin,
a marker of bone turnover, in CN patients. In summary,
there was a linear relationship between impaired AGE
defense (lack of RAGE), increased bone turnover, and
reduced bone stiffness. This study suggests compelling
evidence that drugs that increase RAGE levels, such
as ACE-inhibitors, statins, and glitazones, may be useful
in preventing or suppressing CN.
Conclusion
With an increasing prevalence of diabetes, there will
be a rising incidence of CN, along with a higher rate of
the associated devastating foot and ankle complications.
The exact pathogenesis of CN remains elusive; however,
it is known that sensory and autonomic neuropathy
are prerequisite to begin the process of uncontrolled
inflammation through proinflammatory cytokines TNF-
alpha and interleukins, unchecked activation of RANKL,
and the resulting imbalance of osteoclasts and osteo-
blasts (16). Neuropathy decreases the available amounts
of CGRP and eNOS that in turn activate RANKL.
Elevated glucose levels form AGEs, and the lack of
Increased blood glucose
Lack of RAGE
Increased AGEs
RANKL
Osteoclasts
BONE DESTRUCTION
IL-6
IL-1
OPG
Repetitive Trauma 
Decreased CGRP
Decreased eNOS
Neuropathy
Neuropathy
Fig. 1. The role of RANKL in Charcot neuroarthropathy.
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isms that have been implicated in the pathogenesis
of CN are the targets of therapeutic agents, including
bisphosphonates, anti-TNF therapy, ACE-inhibitors, sta-
tins, and glitazones.
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